Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHadass Pri ChenEZEran ZimranMAMiri Assayag

Discussion

Loading...

Member takes

Overview

Phase 1 trial demonstrates significant clinical improvement in patients with autoimmune conditions, indicating potential of CAR T-cell therapy.

Key Points

  • Clinical responses observed with BCMA-targeted CAR T-cell therapy across several autoimmune diseases, enhancing treatment options for refractory conditions.
  • Two patients with systemic sclerosis showed significant decreases in skin fibrosis symptoms within two months, as assessed by Modified Rodnan Skin Score.
  • Phase 1 trial involved lymphodepleting chemotherapy followed by CAR T-cell infusion, assessing safety and initial efficacy in autoimmune patients.
  • Positive outcomes suggest BCMA-targeted CAR T-cell therapy may offer new avenues for treatment, though further investigation is needed.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddb4https://doi.org/10.1182/blood-2025-2378
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 2 citations
  2. 2Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients2025
  3. 3Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  4. 4Point of care anti-CD19 CAR-T for autoimmune diseases2025
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025